Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Atreya, Chintamani; Glynn, Simone; Busch, Michael; Kleinman, Steve; Snyder, Edward; Rutter, Sara; AuBuchon, James; Flegel, Willy; Reeve, David; Devine, Dana; Cohn, Claudia; Custer, Brian; Goodrich, Raymond; Benjamin, Richard J.; Razatos, Anna; Cancelas, Jose; Wagner, Stephen; Maclean, Michelle; Gelderman, Monique; Cap, Andrew; Ness, Paul

Currently the biggest ongoing credible blood-borne pathogen threat to the nation's blood supply comes from bacterial contamination. 37 While PR technology can address this, there are other options for mitigating risk of bacterial contamination of PLTs, including performing secondary bacterial cultures and point-of-release immunologic testing. However, should a new viral or other nonbacterial agent threaten the national blood supply, the time to ramp up adequate PR manufacturing infrastructure to meet such a nonbacterial threat would likely be substantial. 38 More widespread adoption of PR technology now would do much to ameliorate the concern over this scenario.